Navin Fluorine International Ltd

- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The company is focused on maintaining a strong balance sheet, with a net debt to equity ratio of 0.38x as of June 2024, reflecting financial strength. - Interest costs have decreased quarter-on-quarter due to efforts like reducing working capital borrowings and negotiating better spread rates with lenders. - Ongoing CAPEX projects (Rs. 540 crore agro-specialty plant, Rs. 450 crore AHF project, Rs. 288 crore cGMP-4, Rs. 84 crore R32 capacity expansion, and Rs. 30 crore new capability in Surat) are advancing as planned, with no mention of raising additional funds for these. - The company emphasizes internal financial discipline and improving cash flow without indicating the need for external fundraising at this time.

- Rs. 540 crore agro-specialty project targeted for commercial production by September FY25; firm purchase orders secured for FY25. - Rs. 450 crore AHF project to enhance HF capacity by 40,000 MT at Dahej, on track to commence by end FY25/early FY26. - Rs. 288 crore cGMP-4 CAPEX underway, planned commissioning by end of calendar year 2025. - Additional R32 CAPEX of Rs. 84 crores to boost capacity by 4,500 tonnes, expected completion by February 2025. - Rs. 30 crore CAPEX for new capability development in Surat, progressing for commissioning in Q2 FY25. - Plans to upscale capacity to aspirational Rs. 100 million in CDMO by FY27, with extra capacity coming on stream late calendar year 2025. - Ongoing upgrades to flexibility at the agro plant to cater to more molecules at customer's cost.

- FY25 expected to see recovery in agrochemical demand in the second half after inventory rationalization. - Rs. 540 crore agro-specialty CAPEX plant to commence commercial production by September FY25, targeting full capacity utilization and meeting firm purchase orders. - FY25 revenues expected to improve with increased capacity utilization and ramp-up of new projects. - FY26 anticipated to see better performance than FY25, driven by new capacities coming online. - FY27 expected to hit Rs. 100 crore aspirations for CDMO business, with significant capacity expansion completing end of calendar year 2025. - R32 capacity expansion (additional 4,500 tonnes) on track to complete by February 2025 to meet strong market demand. - Specialty chemical pipeline growing with new molecules expected to contribute incremental Rs. 60-80 crore revenue by 2027. - Overall revenue growth guided by ramp-up of CAPEX projects and improving market conditions, particularly in second half of FY25 onward.

- FY25 expected to witness gradual recovery in agrochemicals with demand uptick in second half, aiding revenue growth. - CDMO segment to see improvement with increasing late-stage commercial molecules; FY25 better than FY24 anticipated. - FY25 operating EBITDA margin improved sequentially (Q1 at 19.2%), with marginal margin expansion planned through the year. - Rs. 540 crore agrochemical plant to commission in September FY25, expected to contribute peak revenues by FY27. - Capacity expansions (R32, HF, cGMP-4) expected to drive medium-term revenue growth. - FY27 target of Rs. 100 crore revenue in CDMO segment based on new capacity coming online late calendar 2025. - Continuous cost optimization and R&D investments to protect and improve EBIT and ROCE. - Earnings impacted in short term by higher depreciation and interest costs linked to new CAPEX. - Overall, improving margins and rising capacity utilization expected to support earnings and EPS growth post FY25.

- The Rs. 540 crore agrochemical plant, commissioning in September FY25, has firm, non-cancellable orders from a global major. - This order book is part of a mature relationship involving multiple products (4-5) under supply agreements. - For FY25, the plant's capacity utilization is expected to be dedicated 50%, fulfilling existing firm orders. - Additional campaigns (~100 metric tonnes) will be run to qualify products for future orders. - The CDMO business has a strong pipeline; confident that FY25 will be better than FY24. - FY27 is targeted to reach the aspiration of $100 million revenue in CDMO, backed by capacity expansion coming online end of calendar year 2025 (FY26). - Orderbook visibility in CDMO is improving quarter-on-quarter. - Domestic CDMO supplies happen temporarily until product registrations with global majors are complete; then exports commence directly. - Overall, orderbook is robust, backed by long-term supply contracts and ongoing strong customer relationships.